Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Linagliptin in Hepatic Impairment
NCT02183376Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state at Day 12, Maximum concentration at steady state at Day 12 and 2 more. Started Jul 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02183376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02183376.